Molecular Investigation of the Cytotoxic and Apoptotic Effects of Apilarnil and Queen Bee Larvae in MCF-7 Breast Cancer Cells
Abstract
Breast cancer is one of the most common malignancies affecting women. Due to the side effects of conventional treatments, research into naturally occurring alternative therapeutic agents is critically important. This study aimed to comprehensively investigate, for the first time, the anticancer potential of lyophilized male bee larvae (apilarnil) and queen bee larvae, which are new generation apitherapy products, against breast cancer cells. The cytotoxic effects of apilarnil and queen bee larvae were evaluated in MCF-7 (human breast adenocarcinoma) and MCF-12a (healthy breast epithelium) cell lines using the MTT assay. Following the determination of IC₅₀ values, apoptotic cell death mechanisms were examined at the molecular level using quantitative reverse transcription polymerase chain reaction (qRT-PCR). The study analyzed the mRNA expression levels of Bcl-2, Bax, Caspase-3, Caspase-8, and Caspase-9 genes, which play a critical role in apoptosis regulation. Both bee products exhibited potent cytotoxic activity against MCF-7 cancer cells (apilarnil IC₅₀: 7.7 µg/mL; queen bee larvae IC₅₀: 15.9 µg/mL). Molecular analyses revealed that these products increased the expression of proapoptotic genes (Bax, Caspase-3, Caspase-8, and Caspase-9) by 2-8-fold and significantly downregulated the anti-apoptotic Bcl-2 gene. A proliferative effect was observed in healthy MCF-12a cells at the same concentrations, indicating selective anticancer activity. This study demonstrates, for the first time, that apilarnil and queen bee larvae exhibit potent and selective cytotoxic effects against breast cancer cells. The findings indicate that these apitherapeutic products target cancer cells by activating apoptotic pathways. The results suggest that these natural products have potential as adjuvant therapies in future breast cancer treatments and provide a robust foundation for subsequent in vivo research in this field.
Keywords
Bee products, breast cancer, cell death, cytotoxicity, natural anticancer agents
Ethical Statement
References
- Abd El‐Wahed, A. A., Khalifa, S. A., Aldahmash, B., Zhang, H., Du, M., Zhao, C., . . . & El‐Seedi, H. R. (2024). Exploring the chemical constituents and nutritive potential of bee drone (Apilarnil): emphasis on antioxidant properties. Chemistry and Biodiversity, 21(5), e202400085. https://doi.org/10.1002/cbdv.202400085
- American Cancer Society. (2018). What causes cancer? https://www.cancer.org/cancer/cancercauses.html
- Aoşan, C. (2016). Apitherapy in the daily practice — Clinical applications [Conference presentation]. Apimedica and Apiquality Forum, Rome, Italy.
- Arnold, M., Morgan, E., Rumgay, H., Mafra, A., Singh, D., Laversanne, M., . . . & Soerjomataram, I. (2022). Current and future burden of breast cancer: Global statistics for 2020 and 2040. The Breast, 66, 15–23. https://doi.org/10.1016/j.breast.2022.08.010
- Babacan, A. A., & Ayar, A. (2024). Effects of apilarnil and queen bee larvae on larval mortality and longevity in Drosophila melanogaster. Uludağ Arıcılık Dergisi, 24(2), 223–234. https://doi.org/10.31467/uluaricilik.1494204
- Badisa, R. B., Darling-Reed, S. F., Joseph, P., Cooperwood, J. S., Latinwo, L. M., & Goodman, C. B. (2009). Selective cytotoxic activities of two novel synthetic drugs on human breast carcinoma MCF-7 cells. Anticancer Research, 29(8), 2993–2996.
- Balkanska, R., Karadjova, I., & Ignatova, M. (2014). Comparative analyses of chemical composition of royal jelly and drone brood. Bulgarian Chemical Communications, 46(2), 412–416.
- Bărnuţiu, L. I., Mărghitaş, L. A., Dezmirean, D., Bobiş, O., Mihai, C., & Pavel, C. (2013). Physico-chemical composition of apilarnil (bee drone larvae). Lucrări Ştiinţifice—Seria Zootehnie, 59, 199–202.
- Borum, A. E. (2024). Apitherapy and applications in veterinary medicine. Uludağ Arıcılık Dergisi, 24(2), 442–458. https://doi.org/10.31467/uluaricilik.1537629
- Cacan, E., Spring, A. M., Kumari, A., Greer, S. F., & Garnett-Benson, C. (2015). Combination treatment with sublethal ionizing radiation and the proteasome inhibitor, bortezomib, enhances death-receptor mediated apoptosis and anti-tumor immune attack. International Journal of Molecular Sciences, 16(12), 30405–30421. https://doi.org/10.3390/ijms161226238